TLIS: Pangali EV/EBITDA Talis Biomedical Corporation

Talis Biomedical is expanding its network of partnerships with laboratory centers to implement rapid diagnostic systems. Talis Biomedical relies on the Talis One platform, which enables high-precision molecular assays directly within the clinic. This market valuation chart for the company on GURU.Markets reflects a value of , however, the current business status is critical due to delisting and a complete cessation of operational activities.

This multiple compares the total business value, including net debt, with its ability to generate cash flow before taxes and depreciation. An analysis of the enterprise value to EBITDA ratio allows for the determination of the real value of assets relative to their operational efficiency. For Talis Biomedical (TLIS), this indicator is critical, as it reflects the risk of capital loss amid workforce reductions and the mothballing of core capacities.